)
){kind=logo}
Our featured content
Buynomics Secures $30M Million in Series B Funding to Expand AI-driven Commercial Operating System
Buynomics, a leader in AI-powered pricing and revenue optimization, has raised $30M in Series B funding. The round was led by Forestay Capital, with participation from Anais Ventures, VI Partners, and existing investors Insight Partners, Seedcamp, DvH Ventures, and Tomahawk Ventures.
)
SaaS veteran and long-time Nexthink C-level executive Yassine Zaied joins Vi Partners as Operating Partner
A SaaS veteran and longtime C-level executive at Nexthink, Yassine was instrumental in establishing Digital Employee Experience (DEX) management as a category, helping position Nexthink as a global leader in Gartner’s rankings. Now, he brings his go-to-market expertise and category creation mindset to support our portfolio companies in scaling to new heights.
)
Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech
Taiho Pharmaceutical to acquire Araris Biotech for $400M+ with potential up to $1.14 billion!
)
Kadoa Secures Funding to Scale AI Agents for Unstructured Data
Kadoa, a company building AI agents for unstructured data, is pleased to announce the successful completion of its latest funding round. The investment was led by Vi Partners, with participation from Fyrfly Venture Partners.
)
Unique Secures USD $30 Million Series A to Pioneer Agentic AI Workforce in Financial Services
This round is led by CommerzVentures and DN Capital, with continued support from existing seed investors including VI Partners and Pictet Group.This funding will accelerate product development and fuel Unique’s ambitious global expansion plans, particularly into the United States.
)
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
With its share price holding steady above $20, the company is on track to achieve hashtag unicorn status as soon as next week! 🦄
)
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients with NLRC4 mutation and XIAP deficiency
)
Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval
Xeltis completed the enrolment of 120 patients with end-stage renal disease in 22 centers in Europe.
){kind=logo}
CeQur Closes a $120M Equity Financing to Drive Commercial Growth
The financing secured will drive growth and accelerate commercial expansion efforts, support the scaling of commercial teams and outreach initiatives to bring CeQur Simplicity™, its 4-day wearable insulin delivery device, to more healthcare providers and patients managing diabetes
)
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis
Oculis announced positive topline results with OCS-05 in the Phase 2 ACUITY trial, which met the primary endpoint of safety and achieved statistical significance on several key efficacy-based secondary endpoints. The trial evaluated the safety, tolerability and efficacy of OCS-05, a neuroprotective candidate, in patients with acute optic neuritis.
Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co.
Araris announced they have entered a Research Collaboration and Option to License Agreement under which Araris will use its proprietary linkerconjugation platform, AraLinQTM, to generate novel ADCs using antibodies against undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. ("Chugai").
)
Oplit welcomes Vi Partners as a new investor to accelerate its European expansion and strengthen R&D investments
Oplit, a software provider of planning and optimization solutions for Industry 4.0, has announced the completion of a new funding round. The amount of the investment has not been disclosed. The round was led by Vi Partners with participation from existing investors OSS Ventures, Newfund, Evolem, and BACS Innov.
)
RealWear acquires smartglasses innovator Almer to supercharge the industrial adoption of wearables, backed by TeamViewer
In a move set to reshape the industrial Augmented Reality (AR) market, RealWear, the global leader in wearable computing for industrial applications, today announced its acquisition of Vi Partner’s portfolio company, Almer Technologies, a Swiss pioneer in ultra-compact, user-friendly AR headsets.
)
Vara raises $8.9 million to expand AI-enabled early breast cancer detection to India
Vi Partners is pleased to announce that our portfolio company, Vara, a pioneering AI-enabled early breast cancer detection platform, has successfully raised $8.9 million in funding. The round welcomed three new lead investors: European family offices Smart Family Office (Austria) and FJH (Germany), as well as Berlin-based healthcare investor IBB Ventures.
)
Vara's Groundbreaking Research Demonstrates Potential of AI to Transform Breast Cancer Detection Worldwide
A new study published in The Lancet Digital Health today highlights the potential of different approaches to using AI to enhance cancer detection and improve efficiency in mammography screening programs.
)
Somagenetix secures CHF 10 million in Series A round
Somagenetix AG, a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders, announced today the initial closing of its Series A financing round, raising CHF 10 million.
)
Almer Technologies secures 3 million USD in new funding round, led by Vi Partners
Vi Partners, Switzerland’s leading venture capital firm, has led a new funding round of 3 million USD in Almer Technologies. Kickfund also participated in this investment, which will help Almer accelerate its innovation in Augmented Reality (AR).
)
FLOWIT AG Successfully Closes Oversubscribed First Funding Round: 4MM CHF 🚀
FLOWIT AG, an innovative Swiss start-up that is revolutionising traditional approaches to personnel development with its AI-based "digital coach," is pleased to announce the successful completion of its first and oversubscribed 4 million CHF seed funding round.
)
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Edwards Lifesciences today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.
)
How Sibylla Biotech is using AI to solve the problem of non-druggable targets
Artificial Intelligence is revolutionising healthcare by automating tasks and enhancing diagnostics and treatments. Startups are particularly focusing on AI to tackle diseases caused by non-druggable proteins, which have long been a challenge in medicine. Sibylla Biotech, a Vi Partners portfolio company, is using machine learning to develop innovative treatments targeting these elusive proteins, potentially unlocking breakthroughs in biotech and pharmaceuticals. Learn more about the impact of AI on healthcare and how companies like Sibylla Biotech are leading the way in our latest blog post.
)
Latest News
-
Portfolio – Apr 07, 2025 )
)
Portfolio – Mar 20, 2025 Next-generation Revenue Intelligence Software Buynomics Secures $30M Million in Series B Funding to Expand AI-driven Commercial Operating System
)
Firm – Mar 18, 2025 SaaS veteran and long-time Nexthink C-level executive Yassine Zaied joins Swiss VC Vi Partners as Operating Partner to accelerate scaleups
)
Entrepreneurs improve the world. We proudly support them.
Our heritage
Who we are and how we started
Vi Partners' founding team came together in 2000 to advise Venture Incubator, an investment vehicle initiated by ETHZ and funded by ten blue-chip Swiss companies. Today, we advise funds investing across Europe in tech and healthcare.
)